Fig. 6.

TAX2 efficacy in a metastatic mouse model of ovarian cancer. a A metastatic ovarian carcinoma model was established in C57BL/6 J female mice by IP injection of 2 × 10⁶ ID8 Trp53^−/− Brca2^−/− cells. Tumor burden was monitored by assessing the change in relative body weight as a result of intense ascites production over 6 weeks post inoculation with tumor cells. Plasma TSP-1 concentration was quantified using an ELISA assay. b C57BL/6 J female mice (n = 9–19 per group) were IP inoculated with ID8 Trp53^−/− Brca2^−/− cells and treated the following day with either olaparib (50 mg/kg, per os, daily for 2 weeks) or TAX2 (30 mg/kg, IV, 3 times weekly for 6 weeks). Kaplan–Meier overall survival analysis illustrates the outcome among control mice (black), olaparib (orange), and TAX2 treated mice (blue). Survival curves were compared using the Gehan–Breslow–Wilcoxon test as previously described [37]. The table presents median survival for each treatment group. c C57BL/6 J female mice were IP injected with ID8 Trp53^−/− Brca2.^−/− and treated with vehicle (n = 9), olaparib alone (50 mg/kg, per os, daily for 2 weeks, n = 20) or sequentially with olaparib (50 mg/kg, per os, daily for 2 weeks) followed by TAX2 (30 to 100 mg/kg, IV, 3 times weekly for 4 weeks) (n = 8 per TAX2 dosing). The left panel indicates the tumor response, with the dotted black circle representing mice unresponsive to olaparib treatment. The right panel presents Kaplan–Meier overall survival analysis comparing control mice (black, n = 9), olaparib-resistant mice (orange, n = 14), and mice treated sequentially with olaparib then TAX2 (30 mg/kg, green, n = 19), using the Gehan–Breslow–Wilcoxon test. *p < 0.05, ***p < 0.001